Products
Samrotamab Biosimilar Antibody-Drug Conjugate (LRRC15) for Research
Pre-Made Samrotamab biosimilar, Whole mAb ADC, Anti-LRRC15 Antibody: Anti-LIB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-505-1mg | 1mg | 4635 |
| GMP-Bios-ab-505-10mg | 10mg | |
| GMP-Bios-ab-505-100mg | 100mg | |
| GMP-Bios-ab-505-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Samrotamab biosimilar, Whole mAb ADC, Anti-LRRC15 Antibody: Anti-LIB therapeutic antibody |
| INN Name | Samrotamab |
| Target | LRRC15 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | AbbVie |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Solid tumours |
| Development Tech | na |
About target - LRRC15
1. Protein Leucine-rich repeat-containing protein 15
2. Gene LRRC15
3. Organism Homo sapiens (Human)
Function
